IL13 (Interleukin 13) is a cytokine with a weight of 12-kDa, expressed by CD4 T helper 2 (Th2) cells, basophils, eosinophils, mast cells, invariant natural killer T cells, and type 2 innate lymphoid cells. IL-13 is primarily produced by TH2 cells, but it is also secreted by other T helper cell subsets CD8+ T cells, mast cells, eosinophils and basophils following activation. IL-13 induces proliferation and immunoglobulin E (IgE) synthesis by human B cells, suggesting that it may play a role in the pathogenesis of IgE-mediated allergic diseases. Moreover, IL-13 inhibits production of proinflammatory cytokines and chemokines by monocytes/macrophages both in vitro and in vivo, indicating that IL-13 also has important anti-inflammatory properties. IL17A (Interleukin 17A), also referred to IL17 or CTLA8 (Cytotoxic T-lymphocyte-associated serine esterase 8), is a 17.5 kDa glycoprotein encoded in humans by the IL17A gene that is located at the chromosome 6p12.2. It is composed of 155 amino acids and belongs to the IL17 protein family (IL17A- IL17F), of which each monomer contains four highly conserved cysteine residues. IL17A is a proinflammatory cytokine released by CD4+ T cells (Th17 cells), CD8+ T cells (Tc17 cells), invariant natural killer T cells (iNKT cells), γδ T cells and innate lymphoid cells (ILCs). This cytokine functions in the regulation of activities of NF-kappaB and mitogen-activated protein kinases. Its high levels are associated with several chronic inflammatory diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis.